Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib with Temozolomide and/or Irinotecan in Ewing Sarcoma
NCT02044120Phase 1Completed
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- May 2014
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of niraparib in Ewing sarcoma (3 arms), sponsored by Sarcoma Alliance for Research through Collaboration. Primary endpoint: Dose-limiting toxicity and maximum tolerated dose at 24 months. Started May 2014; status: completed.
02
Drugs
niraparib
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT02044120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044120.